E
Evosep
Biotech & Life Sciences · Odense, Denmark · Founded 2016
Develops new solutions to make clinical proteomics 100 times more robust and 10 times faster MoreLess
Evosep is a pioneering company in the field of clinical proteomics, focusing on developing advanced solutions that significantly enhance the robustness and speed of proteomic analyses. The company serves a diverse range of clients, including clinical laboratories, research institutions, and pharmaceutical companies, who require high-throughput and reliable proteomic data. Operating in the rapidly growing proteomics market, Evosep's business model revolves around the sale of specialized instruments and consumables, such as the Evosep One and Evotip, which are designed to streamline and improve the efficiency of proteomic workflows. The company generates revenue through direct sales of these products, as well as through service contracts and partnerships. By addressing the increasing demand for high-throughput and robust proteomic solutions, Evosep aims to bridge the gap between research and clinical applications, ultimately bringing proteomics closer to everyday clinical practice.
Keywords: clinical proteomics, high-throughput, robustness, Evosep One, Evotip, pharmaceutical, research institutions, proteomic workflows, service contracts, specialized instruments.
Company overview
Evosep company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Odense, Denmark
- Employees
- 88
- Open positions
- None listed
- Dealroom signal
- 80.0
Valuation & funding
Evosep funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jan 2023 | $40M | $160M | Novo Nordisk | ↗ |
| OtherOther financing | Jun 2016 | $0 | — | Undisclosed | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | EBITDA | Margin | Profit | Margin | R&D |
|---|---|---|---|---|---|
| 2026 | −$16M | — | $2.9M | — | $0 |
| 2025 | −$16M | — | $2.9M | — | $0 |
| 2024 | −$16M | — | $2.9M | — | $0 |
| 2023 | −$16M | — | $0 | ||
| 2022 | −$16M | — | |||
| 2021 | $3.2M | — | |||
| 2020 | $1.3M | — |
Growth signals
Evosep website traffic
Latest recorded traffic for Evosep is 11K monthly website visits, down 31.3% over the last three months. Evosep's team grew 11.4% over the past year.
Comparisons
Evosep compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Evosep's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Evosep's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Evosep has talent and traffic
team presence
In the news
Latest news about Evosep
Recent press, funding announcements, and product moves mentioning Evosep — open to read from the original sources.
Market sentiment
What the market is saying about Evosep
An AI-synthesized read of the highest-engagement posts about Evosep on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evosep’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.